Bayer (FRA:BAYN) Given a €77.00 Price Target by Credit Suisse Group Analysts
Credit Suisse Group set a €77.00 ($89.53) target price on Bayer (FRA:BAYN) in a research report sent to investors on Wednesday, November 14th. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other research analysts have also recently issued reports on BAYN. Independent Research set a €85.00 ($98.84) price objective on Bayer and gave the stock a neutral rating in a research report on Wednesday, September 5th. Commerzbank set a €111.00 ($129.07) price objective on Bayer and gave the stock a buy rating in a research report on Monday, August 13th. Baader Bank set a €140.00 ($162.79) target price on Bayer and gave the company a buy rating in a research report on Wednesday, August 1st. Barclays set a €110.00 ($127.91) target price on Bayer and gave the company a buy rating in a research report on Monday, August 13th. Finally, JPMorgan Chase & Co. set a €120.00 ($139.53) target price on Bayer and gave the company a buy rating in a research report on Monday, August 13th. Six analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Bayer currently has a consensus rating of Buy and an average target price of €90.80 ($105.58).
BAYN traded up €1.06 ($1.23) on Wednesday, hitting €63.43 ($73.76). 5,377,233 shares of the company were exchanged. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: How to use beta for portfolio diversification
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.